Kazia Therapeutics Ltd ADR KZIA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KZIA is a good fit for your portfolio.
News
-
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
-
Kazia Therapeutics Announces $2 Million Registered Direct Offering
-
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
-
KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
-
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
-
KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
-
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA
-
KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA
Trading Information
- Previous Close Price
- $0.45
- Day Range
- $0.40–0.49
- 52-Week Range
- $0.32–1.68
- Bid/Ask
- $0.47 / $0.50
- Market Cap
- $10.86 Mil
- Volume/Avg
- 8 / 83,535
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
Valuation
|
Metric
|
KZIA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.31 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KZIA
|
|---|---|
Quick Ratio | 0.71 |
Current Ratio | 1.42 |
Interest Coverage | — |
Quick Ratio
KZIA
Profitability
|
Metric
|
KZIA
|
|---|---|
Return on Assets (Normalized) | −73.91% |
Return on Equity (Normalized) | −161.92% |
Return on Invested Capital (Normalized) | −147.35% |
Return on Assets
KZIA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xlfnq | $451.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gjjwbtk | $91.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qqkks | $89.4 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Prmxyn | $40.7 Bil | |
MRNA
| Moderna Inc | Xffsp | $29.8 Bil | |
ARGX
| argenx SE ADR | Tmvfp | $27.8 Bil | |
BNTX
| BioNTech SE ADR | Cnbm | $23.5 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wmflvkq | $21.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jkfmp | $17.6 Bil | |
INCY
| Incyte Corp | Wzqcvw | $12.3 Bil |